Sandrine Hiret

机构：Institut de Cancérologie de l'Ouest · ORCID：0000-0002-3789-8171

发表论文 162 篇 · 总被引 12522 次 · h-index 24

代表论文

• Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study (2025 · Journal of Thoracic Oncology · 被引 16)
• Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). (2025 · Journal of Clinical Oncology · 被引 5)
• Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial (2026 · Nature Medicine · 被引 3)
• MA08.03 First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2 (2025 · Journal of Thoracic Oncology · 被引 2)
• First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors (2026 · Journal for ImmunoTherapy of Cancer · 被引 1)
• Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. (2025 · Journal of Clinical Oncology · 被引 1)